Atea Pharmaceuticals Unveils Antiviral Pipeline Progress and Phase 3 HCV Trial Updates

Reuters01-15

Atea Pharmaceuticals Unveils Antiviral Pipeline Progress and Phase 3 HCV Trial Updates

Atea Pharmaceuticals Inc. provided an update on its focused antiviral pipeline at the 44th Annual J.P. Morgan Healthcare Conference. The company highlighted progress with its fixed-dose combination of bemnifosbuvir (BEM) and ruzasvir (RZR) for hepatitis C virus (HCV), noting completion of enrollment for the Phase 3 C-BEYOND trial in the US and Canada, with results expected in mid-2026. Full patient enrollment for the Phase 3 C-FORWARD trial outside North America is also anticipated by mid-2026, with results expected by year-end 2026. Atea reported cash and investments of $301.8 million as of December 31, 2025, and anticipates a cash runway through 2027. The company also announced plans to initiate a Phase 1 trial of its nucleotide prodrug AT-587 for hepatitis E virus (HEV) in mid-2026. Market insights from healthcare professionals underscore the need for shorter, easier-to-use HCV regimens to support rapid test-and-treat models. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atea Pharmaceuticals Inc. published the original content used to generate this news brief on January 15, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603920983?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-15 21:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603920983","market":"us","top_or_hot":-1,"title":"Atea Pharmaceuticals Unveils Antiviral Pipeline Progress and Phase 3 HCV Trial Updates","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Atea Pharmaceuticals Unveils Antiviral Pipeline Progress and Phase 3 HCV Trial Updates\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Atea Pharmaceuticals Inc. provided an update on its focused antiviral pipeline at the 44th Annual J.P. Morgan Healthcare Conference. The company highlighted progress with its fixed-dose combination of bemnifosbuvir (BEM) and ruzasvir (RZR) for hepatitis C virus (HCV), noting completion of enrollment for the Phase 3 C-BEYOND trial in the US and Canada, with results expected in mid-2026. Full patient enrollment for the Phase 3 C-FORWARD trial outside North America is also anticipated by mid-2026, with results expected by year-end 2026. Atea reported cash and investments of $301.8 million as of December 31, 2025, and anticipates a cash runway through 2027. The company also announced plans to initiate a Phase 1 trial of its nucleotide prodrug AT-587 for hepatitis E virus (HEV) in mid-2026. Market insights from healthcare professionals underscore the need for shorter, easier-to-use HCV regimens to support rapid test-and-treat models. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atea Pharmaceuticals Inc. published the original content used to generate this news brief on January 15, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Atea Pharmaceuticals Unveils Antiviral Pipeline Progress and Phase 3 HCV Trial Updates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAtea Pharmaceuticals Unveils Antiviral Pipeline Progress and Phase 3 HCV Trial Updates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-15 21:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Atea Pharmaceuticals Unveils Antiviral Pipeline Progress and Phase 3 HCV Trial Updates\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Atea Pharmaceuticals Inc. provided an update on its focused antiviral pipeline at the 44th Annual J.P. Morgan Healthcare Conference. The company highlighted progress with its fixed-dose combination of bemnifosbuvir (BEM) and ruzasvir (RZR) for hepatitis C virus (HCV), noting completion of enrollment for the Phase 3 C-BEYOND trial in the US and Canada, with results expected in mid-2026. Full patient enrollment for the Phase 3 C-FORWARD trial outside North America is also anticipated by mid-2026, with results expected by year-end 2026. Atea reported cash and investments of $301.8 million as of December 31, 2025, and anticipates a cash runway through 2027. The company also announced plans to initiate a Phase 1 trial of its nucleotide prodrug AT-587 for hepatitis E virus (HEV) in mid-2026. Market insights from healthcare professionals underscore the need for shorter, easier-to-use HCV regimens to support rapid test-and-treat models. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atea Pharmaceuticals Inc. published the original content used to generate this news brief on January 15, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260115:nNDLHXwd9:1","article_id":"2603920983","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603920983","pubTimestamp":1768485387,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Atea Pharmaceuticals Inc. provided an update on its focused antiviral pipeline at the 44th Annual J.P. Morgan Healthcare Conference. The company highlighted progress with its fixed-dose combination of bemnifosbuvir  and ruzasvir  for hepatitis C virus , noting completion of enrollment for the Phase 3 C-BEYOND trial in the US and Canada, with results expected in mid-2026. Full patient enrollment for the Phase 3 C-FORWARD trial outside North America is also anticipated by mid-2026, with results expected by year-end 2026. Atea reported cash and investments of $301.8 million as of December 31, 2025, and anticipates a cash runway through 2027. The company also announced plans to initiate a Phase 1 trial of its nucleotide prodrug AT-587 for hepatitis E virus  in mid-2026. Market insights from healthcare professionals underscore the need for shorter, easier-to-use HCV regimens to support rapid test-and-treat models. You can access the full presentation through the link below.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","AVIR":"Atea Pharmaceuticals, Inc."},"translate_title":"Atea Pharmaceuticals公布抗病毒管道进展和3期HCV试验更新","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AVIR":0.9},"content_text":"Atea Pharmaceuticals Unveils Antiviral Pipeline Progress and Phase 3 HCV Trial Updates\n    \n\n        Atea Pharmaceuticals Inc. provided an update on its focused antiviral pipeline at the 44th Annual J.P. Morgan Healthcare Conference. The company highlighted progress with its fixed-dose combination of bemnifosbuvir (BEM) and ruzasvir (RZR) for hepatitis C virus (HCV), noting completion of enrollment for the Phase 3 C-BEYOND trial in the US and Canada, with results expected in mid-2026. Full patient enrollment for the Phase 3 C-FORWARD trial outside North America is also anticipated by mid-2026, with results expected by year-end 2026. Atea reported cash and investments of $301.8 million as of December 31, 2025, and anticipates a cash runway through 2027. The company also announced plans to initiate a Phase 1 trial of its nucleotide prodrug AT-587 for hepatitis E virus (HEV) in mid-2026. Market insights from healthcare professionals underscore the need for shorter, easier-to-use HCV regimens to support rapid test-and-treat models. You can access the full presentation through the link below.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atea Pharmaceuticals Inc. published the original content used to generate this news brief on January 15, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603920983","isCrawlerRequest":true}